Clinical Reference Guide

Sleep Disorders in Nursing Practice

Comprehensive GCC nursing guide covering sleep physiology, OSA management, insomnia, parasomnias, hospital sleep promotion, and exam preparation.

ICSD-3 Classification DHA / DOH / SCFHS Relevant Evidence-Based Interactive STOP-BANG Screener

Sleep Architecture

NREM Stages

  • N1 (Stage 1): Light sleep, 1–7% of total sleep. Theta waves. Hypnic jerks may occur. Easily awakened.
  • N2 (Stage 2): ~50% of total sleep. Sleep spindles and K-complexes on EEG. Heart rate and temperature decrease.
  • N3 (Slow-Wave Sleep / SWS): Deep restorative sleep, delta waves. Growth hormone secreted. Memory consolidation, tissue repair. Hardest to awaken.

REM Sleep

  • Rapid Eye Movement sleep; ~20–25% of total sleep time.
  • EEG resembles wakefulness (desynchronised, low amplitude).
  • Skeletal muscle atonia (protective—prevents acting out dreams).
  • Vivid dreaming; emotional processing and memory consolidation.
  • REM periods lengthen across the night; longest in final cycles.

Sleep Cycles

One complete cycle (N1 → N2 → N3 → REM) lasts approximately 90 minutes. Adults typically complete 4–6 cycles per night. Early cycles are SWS-dominant; later cycles are REM-dominant.

Circadian Rhythm

Suprachiasmatic Nucleus (SCN)

The master circadian pacemaker located in the anterior hypothalamus. Receives photic input from retinal ganglion cells (melanopsin) via the retinohypothalamic tract.

Melatonin Secretion

  • Produced by the pineal gland under SCN control.
  • Rises ~2 hours before habitual sleep onset (Dim Light Melatonin Onset – DLMO).
  • Peaks between 02:00–04:00; suppressed by blue-spectrum light.
  • Acts as a chronobiotic signal, not a strong sedative.

Sleep Requirements by Age

Age GroupRecommended Sleep
Newborn (0–3 mo)14–17 hours
School-age (6–12 y)9–12 hours
Teenager (13–18 y)8–10 hours
Adult (18–64 y)7–9 hours
Older adult (≥65 y)7–8 hours

ICSD-3 Classification of Sleep Disorders

1. Insomnia Disorders

Chronic insomnia disorder, short-term insomnia, other insomnia. Characterised by difficulty initiating/maintaining sleep with daytime consequences.

2. Sleep-Related Breathing Disorders

Obstructive Sleep Apnoea (OSA), Central Sleep Apnoea (CSA), Sleep-Related Hypoventilation, Sleep-Related Hypoxaemia. Most common: OSA.

3. Central Disorders of Hypersomnolence

Narcolepsy type 1 and 2, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia due to medical/psychiatric conditions.

4. Circadian Rhythm Disorders

Delayed Sleep Phase Disorder (DSPD), Advanced Sleep Phase Disorder (ASPD), Shift Work Disorder, Jet Lag, Irregular Sleep-Wake Rhythm.

5. Parasomnias

NREM-related (sleepwalking, sleep terrors, confusional arousals) and REM-related (REM Sleep Behaviour Disorder, nightmare disorder, sleep paralysis).

6. Sleep-Related Movement Disorders

Restless Legs Syndrome (RLS), Periodic Limb Movement Disorder (PLMD), sleep-related leg cramps, bruxism, rhythmic movement disorder.

Sleep Assessment Tools

Epworth Sleepiness Scale (ESS)

  • Self-report; 8 situations rated 0–3 for likelihood of dozing.
  • Score ≤10: normal. 11–15: excessive daytime sleepiness. ≥16: severe EDS.
  • Does not diagnose cause — screens for excessive sleepiness.

Pittsburgh Sleep Quality Index (PSQI)

  • 19 items covering 7 components (subjective quality, latency, duration, efficiency, disturbances, medication, daytime function).
  • Score >5 indicates poor sleep quality; validated over the previous month.

STOP-BANG Questionnaire

  • 8 yes/no questions; score ≥3: high risk for moderate-severe OSA.
  • High sensitivity (93%) for moderate-severe OSA — excellent screening tool.
  • Widely used in pre-operative and primary care settings.

Berlin Questionnaire

  • 3 categories: snoring/apnoea, daytime sleepiness, hypertension/obesity.
  • High risk = ≥2 positive categories. Used in primary care OSA screening.

Sleep Diary

Two-week prospective diary recording bed/wake times, awakenings, naps, caffeine, medication. Gold standard for insomnia assessment alongside clinical interview.

Polysomnography (PSG) — Gold Standard

Overnight in-lab study measuring: EEG (brain waves/sleep staging), EOG (eye movements — REM detection), EMG (chin/limb muscle tone), SpO2 (oxygen saturation), Airflow (thermistor + pressure transducer), Respiratory Effort (thoracic/abdominal bands), ECG (arrhythmias during events), body position, and video recording.

Home Sleep Apnoea Testing (HSAT): Indicated for adults with high pre-test probability of moderate-severe OSA without significant comorbidities. NOT appropriate if central apnoea, hypoventilation, insomnia, or severe comorbidity suspected.

OSA Definitions & Severity

Key Definitions

  • Apnoea: Complete cessation of airflow ≥10 seconds.
  • Hypopnoea: ≥30% reduction in airflow lasting ≥10 seconds, associated with ≥4% oxygen desaturation (AASM 2012 criteria) or ≥3% desaturation + arousal.
  • AHI (Apnoea-Hypopnoea Index): Number of apnoeas + hypopnoeas per hour of sleep.
SeverityAHI (events/hour)
Mild5–14
Moderate15–29
Severe≥30

Consequences of Untreated OSA

  • Daytime sleepiness — impairs driving (road traffic accidents x3–7 risk), work performance.
  • Cardiovascular: Hypertension (independent risk factor), AF, stroke, heart failure, coronary artery disease.
  • Metabolic: Insulin resistance and type 2 diabetes, dyslipidaemia.
  • Neuropsychiatric: Depression, anxiety, cognitive impairment.
  • Perioperative risk: Increased anaesthetic sensitivity, post-extubation obstruction, opioid sensitivity.
GCC Context: OSA prevalence in Gulf states is high (estimated 8–25% of adults) driven by obesity epidemic, sedentary lifestyle, male demographic predominance, and genetic predisposition. Historically under-diagnosed due to limited sleep medicine services, though this is rapidly improving.

CPAP Therapy — First-Line Treatment

Mechanism & Titration

Continuous Positive Airway Pressure (CPAP) delivers a fixed pneumatic splint preventing upper airway collapse. Pressure titrated via in-lab PSG titration or APAP auto-titration (most common initial approach).

Mask Types

  • Nasal mask: Covers nose only; most common. Requires mouth closure.
  • Full-face mask: Covers nose and mouth; for mouth-breathers or high pressure.
  • Nasal pillow: Minimal contact; good for claustrophobic patients, well-tolerated.

Adherence Definition

Adequate adherence: ≥4 hours/night on ≥70% of nights over 30 days (CMS/AASM definition). Insurance and funding often requires objective data download.

CPAP Troubleshooting

  • Mask leak: Refit/resize mask; check head strap tension. Large leaks reduce efficacy.
  • Claustrophobia: Desensitisation (wear mask awake), nasal pillow trial.
  • Dry mouth/nasal dryness: Heated humidifier attachment (most modern CPAP units).
  • Pressure intolerance: Ramp feature (gradual pressure increase), APAP trial, EPR/pressure relief settings.
  • Aerophagia: Reduce pressure (APAP), positional changes, consider BiPAP.
  • Skin irritation: Mask liners, different mask material, ensure clean skin before use.

APAP & BiPAP

  • APAP: Auto-titrating PAP; adjusts pressure breath-to-breath. Useful for variable needs (positional, REM-related OSA).
  • BiPAP: Separate inspiratory/expiratory pressures; for complex OSA, treatment-emergent central apnoea, COPD-OSA overlap, hypoventilation syndromes.

Alternative & Surgical Treatments

Positional Therapy

For positional OSA (AHI ≥2× higher supine vs non-supine). Devices: tennis ball technique, positional pillows, wearable vibrotactile devices (e.g. Night Shift). Useful for mild-moderate positional OSA.

Mandibular Advancement Splint (MAS)

Custom dental device advancing mandible 50–70% of maximum protrusion. Effective for mild-moderate OSA or CPAP-intolerant patients. Side effects: TMJ discomfort, tooth soreness (usually transient).

Surgical Options

  • UPPP (Uvulopalatopharyngoplasty): Removes uvula, soft palate tissue, tonsils. Success rate ~50%; not curative for severe OSA. Post-op pain significant.
  • Hypoglossal nerve stimulation (Inspire): Upper airway stimulator for CPAP-intolerant moderate-severe OSA (non-concentric collapse on DISE).
  • Weight loss surgery: Bariatric surgery significantly reduces AHI in obese patients.

Nursing Role in OSA Management

  • CPAP initiation education: Mask fitting, equipment cleaning (weekly wash), humidifier use, device download/data monitoring, reporting leak/residual AHI issues to sleep team.
  • Adherence support: Motivational interviewing, normalising struggles, identifying barriers, troubleshooting guides, early telephone/clinic follow-up (1–4 weeks post-commencement).
  • Pre-operative OSA risk: Screen using STOP-BANG; document OSA status and CPAP use in anaesthetic pre-assessment. Ensure patient brings CPAP device to hospital.
  • Post-operative airway management: OSA patients at high risk of post-extubation obstruction, oxygen desaturation particularly in first 24 hours when REM rebound occurs. Semi-recumbent positioning, continuous SpO2 monitoring, avoid prone/supine where possible. Resume CPAP as soon as surgically safe.
  • Opioid caution: OSA increases respiratory depression risk with opioids. Discuss with anaesthetic/pain team regarding multimodal analgesia strategies.

Insomnia — Definition & Types

Chronic Insomnia Disorder (ICSD-3): Difficulty initiating sleep (sleep onset latency >30 min), difficulty maintaining sleep (WASO >30 min), or early morning awakening; occurring ≥3 nights/week for ≥3 months, causing daytime impairment, despite adequate sleep opportunity.

Acute Insomnia

Duration <3 months; often precipitated by identifiable stress (bereavement, illness, travel). Resolves when stressor resolves in many, but may become chronic if perpetuating factors develop.

Chronic Insomnia

Explained by Spielman's 3P model: Predisposing (genetics, anxiety trait), Precipitating (life events), Perpetuating (compensatory behaviours — napping, extending time in bed, worry about sleep).

Daytime Impairment Symptoms

  • Fatigue and malaise
  • Impaired concentration and memory
  • Mood disturbance (irritability, anxiety, low mood)
  • Reduced work/school performance
  • Increased accidents and errors
  • Somatic symptoms (headache, GI)

CBT-I — First-Line Treatment

Cognitive Behavioural Therapy for Insomnia (CBT-I) is the evidence-based first-line treatment for chronic insomnia (superior to pharmacotherapy long-term). Typically 4–8 sessions.

Sleep Restriction Therapy

Restricts time in bed to actual sleep time (minimum 5.5 hours), building homeostatic sleep pressure and consolidating sleep. Time in bed extended by 15 min per week once sleep efficiency >85%.

Stimulus Control

  • Bed only for sleep and sex — not reading, screens, eating.
  • Leave bed if unable to sleep within 20 min (do a quiet activity in dim light; return when sleepy).
  • Wake at the same time every day regardless of sleep quality.
  • Avoid daytime napping (initially).

Cognitive Restructuring

Identify and challenge unhelpful sleep-related beliefs: "I must get 8 hours or I'll fall apart," "I can't function on less than 7 hours." Replace with evidence-based perspectives.

Sleep Hygiene Education

  • Consistent sleep and wake times.
  • Avoid caffeine after 14:00; avoid alcohol (disrupts REM).
  • Cool, dark, quiet bedroom environment.
  • Wind-down routine 30–60 min pre-bed (no screens/blue light).
  • Regular daytime exercise (not within 2 hours of bed).

Relaxation Techniques

Progressive muscle relaxation, mindfulness-based approaches, diaphragmatic breathing. Reduces physiological hyperarousal.

Pharmacological Treatment of Insomnia

Z-Drugs (Non-Benzodiazepine Hypnotics)

  • Zolpidem, Zopiclone, Zaleplon: Short-term use only (2–4 weeks). Act on GABA-A receptors.
  • Risks: Rebound insomnia on cessation, dependence, parasomnias (complex sleep behaviours), fall risk in elderly, next-day sedation.
  • Avoid in elderly, COPD, sleep apnoea, pregnancy.

Benzodiazepines

  • Temazepam, nitrazepam; significant dependence and tolerance risk.
  • Suppress N3 SWS; increase fall risk. Very short-term use only.

Melatonin

  • Low-dose (0.5–2 mg) for circadian phase-shifting. 2 mg prolonged-release (Circadin) licensed for insomnia in ≥55 years in some countries.
  • Safe profile; minimal dependency risk.

Low-Dose Sedating Antidepressants

  • Mirtazapine 7.5–15 mg: Antihistaminergic; useful if concurrent depression.
  • Low-dose doxepin (3–6 mg): Approved for sleep maintenance insomnia (H1 antagonism).
  • Trazodone: Commonly used off-label; avoid in cardiac disease.

Orexin Receptor Antagonists

  • Suvorexant (Belsomra), Lemborexant: Block orexin/hypocretin wake-promoting signals.
  • Approved for sleep onset and maintenance insomnia. Preserves sleep architecture better than older hypnotics.
  • Lower dependency risk; avoid in narcolepsy.
Nursing Alert: All hypnotics increase fall risk, especially in elderly. Review regularly; never abrupt discontinuation after prolonged use.

Circadian Rhythm Disorders

Delayed Sleep Phase Disorder (DSPD)

Unable to fall asleep until 02:00–06:00; awakens late morning/afternoon. Common in teenagers (biological phase delay in puberty). Normal sleep quality within chosen timing. Treatment: morning bright light therapy (10,000 lux, 30 min after wake), low-dose evening melatonin (0.5 mg, 6 hours before desired sleep onset), chronotherapy.

Advanced Sleep Phase Disorder (ASPD)

Sleep onset at 18:00–21:00; early morning waking (03:00–05:00). More common in older adults. Treatment: evening bright light therapy.

Shift Work Disorder

Insomnia and/or excessive sleepiness aligned with work schedule conflicts with circadian system. Highly prevalent in GCC healthcare workers (nursing, emergency services). Increased risk of CV disease, metabolic syndrome, depression, breast cancer (prolonged shift work).

Jet Lag

Transient misalignment after rapid transmeridian travel. Eastward travel harder than westward (phase advance harder). Recovery: 1 day per time zone. Managed with timed melatonin and light exposure.

Treatment: Light Therapy

  • 10,000 lux full-spectrum light box; 20–30 minutes each morning (or appropriately timed).
  • Avoid blue-light–emitting screens 2 hours before bed.
  • Timing is critical — depends on the direction of desired phase shift.

Ramadan Sleep Changes (GCC)

During Ramadan, sleep patterns in GCC shift dramatically: main sleep period moves from night to early morning (post-Suhoor); nocturnal social activity peaks. Patients experience sleep deprivation and phase delay. Healthcare workers on Ramadan night shifts face compounded challenges. Clinicians should ask about Ramadan timing when assessing sleep complaints.

Cultural Note: Qailulah (afternoon nap) is an established Islamic practice. Research supports a 20–30 min post-noon nap for alertness restoration — reassure patients that planned napping is not pathological.

Narcolepsy

Symptoms (Tetrad)

  • Excessive Daytime Sleepiness (EDS): Irresistible sleep attacks lasting minutes; refreshed briefly. The cardinal symptom of all narcolepsy.
  • Cataplexy: Sudden bilateral muscle weakness/atonia triggered by strong emotion (laughter, surprise). Fully conscious. Pathognomonic of Type 1. Ranges from jaw drop to full collapse.
  • Sleep paralysis: Inability to move at sleep onset/offset while conscious. Often frightening; resolves seconds–minutes. Benign in isolation.
  • Hypnagogic/Hypnopompic hallucinations: Vivid, often frightening hallucinations at sleep onset (hypnagogic) or awakening (hypnopompic).

Type 1 vs Type 2

  • Type 1 (with cataplexy): Low CSF hypocretin-1 (orexin) level (<110 pg/mL). Autoimmune destruction of hypothalamic orexin neurons (HLA-DQB1*06:02 association). PSG/MSLT: short sleep latency (<8 min) and ≥2 SOREMPs (Sleep-Onset REM Periods).
  • Type 2 (without cataplexy): Normal CSF hypocretin. Diagnosed by MSLT criteria. May be forme fruste of Type 1.

Treatment

  • EDS: Modafinil/armodafinil (first-line stimulants, lower abuse potential); methylphenidate, amphetamines (second-line).
  • Cataplexy: Venlafaxine or clomipramine (REM-suppressant); sodium oxybate (GHB — also improves EDS and night-time sleep; controlled drug).
  • Pitolisant: Histamine H3 receptor antagonist; novel option for EDS and cataplexy.
  • Planned daytime naps (20 min) improve alertness.

Other Hypersomnias

Idiopathic Hypersomnia

EDS without cataplexy; prolonged sleep (10–14 hours), severe sleep inertia (sleep drunkenness). Normal or prolonged MSLT latency; <2 SOREMPs. Normal CSF hypocretin. Management: modafinil, clarithromycin (augments GABA-A antagonism), flumazenil.

Kleine-Levin Syndrome

Rare recurrent hypersomnia: episodes of hypersomnia (16–20 hours/day) lasting days–weeks, with hyperphagia, hypersexuality, cognitive impairment, and altered perception. Between episodes: completely normal. Predominantly affects adolescent males. No effective treatment; lithium may reduce episode frequency. Episodes become less frequent over years.

Parasomnias

NREM Parasomnias (Disorders of Arousal)

Occur in first third of night (N3 SWS). Patient partially aroused — not fully awake. Amnesia for episodes is typical.

  • Sleepwalking (Somnambulism): Ambulation during sleep. Common in children (15%); usually resolves by adolescence. Triggers: sleep deprivation, fever, medications (zopiclone). Safety measures essential (stair gates, door alarms).
  • Sleep Terrors (Night Terrors): Sudden terror with screaming, autonomic arousal (tachycardia, diaphoresis), inconsolable. Eyes open but unresponsive. No memory. Reassure parents — benign and self-limiting in children.
  • Confusional Arousals: Mental confusion upon arousal, inappropriate behaviour, disorientation. Common in young children.

REM Sleep Behaviour Disorder (RBD)

Loss of normal REM muscle atonia; patient physically acts out vivid, often violent dreams (punching, kicking, shouting). Usually injures self or bed partner. Occurs in second half of night.

Clinical Pearl: RBD is a prodrome for alpha-synucleinopathies — up to 90% of idiopathic RBD patients develop Parkinson's Disease, Dementia with Lewy Bodies, or MSA within 10–15 years. Requires neurological follow-up.

Confirmed by PSG showing REM without atonia. Treatment: clonazepam 0.5–2 mg nocte (most effective); melatonin 3–12 mg (safer in elderly; preferred in PD).

Isolated Sleep Paralysis

Benign; occurs in general population (up to 40% lifetime prevalence). Reassure patient it is temporary and harmless. Part of narcolepsy tetrad if recurrent with EDS.

Sleep-Related Movement Disorders

Restless Legs Syndrome (RLS)

Uncomfortable urge to move the legs (less commonly arms), usually worse at rest and in the evening, relieved by movement. Interferes with sleep onset.

  • Primary RLS: Genetic; positive family history in 50%.
  • Secondary RLS: Iron deficiency (check ferritin — treat if <75 µg/L), uraemia (dialysis patients), pregnancy, peripheral neuropathy.
  • Investigations: Serum ferritin, iron studies, renal function, folate, B12, glucose.

RLS Treatment

  • Treat underlying cause (IV/oral iron if deficient).
  • Dopamine agonists: Pramipexole, ropinirole (risk: augmentation — worsening over time, earlier onset, spread to arms). Cabergoline.
  • Alpha-2-delta ligands: Pregabalin, gabapentin — preferred for patients at risk of augmentation or with comorbid pain/anxiety.
  • Opioids (oxycodone ER/naloxone) for refractory RLS.

Periodic Limb Movement Disorder (PLMD)

Repetitive stereotyped limb movements during sleep (ankle dorsiflexion/knee flexion), occurring every 20–90 seconds. Diagnosed on PSG (PLMS index >15/hour). Only clinically significant if causing sleep disturbance (frequent arousals, EDS). Treatment: similar to RLS — dopamine agonists, pregabalin.

Sleep Bruxism

Repetitive jaw muscle activity (grinding/clenching) during sleep. Leads to tooth wear, jaw pain, headache, TMJ disorder. Diagnosis: clinical (dental examination) or PSG. Management: occlusal splint (custom dental guard), stress management, avoid caffeine/alcohol. Botulinum toxin injection to masseter for severe cases.

Why Hospitalisation Disrupts Sleep

Environmental Factors

  • Noise: alarms, staff conversations, trolleys, door banging (average ICU noise: 60–80 dB)
  • Light: 24-hour artificial lighting disrupts circadian melatonin rhythm
  • Uncomfortable bed/temperature
  • Unfamiliar environment (first-night effect)

Clinical Factors

  • Frequent vital sign and blood glucose checks
  • Medication administration at night
  • Procedural pain and anxiety
  • IV lines, catheters, monitoring leads
  • Nocturia (diuretic timing, BPH)
  • Dyspnoea, discomfort, nausea

Pharmacological Factors

  • Corticosteroids: stimulant effect
  • Beta-blockers: suppress melatonin
  • Diuretics: nocturia
  • Sedatives/opioids: suppress N3/REM, rebound insomnia
  • Bronchodilators: tachycardia
Poor hospital sleep is associated with increased pain sensitivity, impaired immune function, delayed wound healing, prolonged delirium, longer length of stay, and reduced patient satisfaction scores.

Sleep Promotion Bundle — Nursing Interventions

Environmental Modifications

  • Dim lights 21:00–06:00 in ward areas; consider circadian-appropriate lighting systems.
  • Provide ear plugs and eye masks to patients (evidence supports reduction in delirium in ICU).
  • Noise reduction campaign: call bell management, staff reminders about conversation volume, lubricating squeaky wheels, closing doors.
  • Maintain comfortable room temperature (18–22°C).

Care Scheduling

  • Cluster care activities — batch essential nursing tasks to minimise night-time interruptions for stable patients.
  • Minimise unnecessary night-time vital signs checks in clinically stable patients (reassess frequency orders).
  • Reschedule diuretics to morning where clinically appropriate.
  • Schedule medications to avoid waking patients if possible.

Non-Pharmacological Comfort Measures

  • Adequate pain assessment and analgesia before sleep.
  • Warm drinks (non-caffeinated) before sleep.
  • Mouth care and positioning comfort.
  • Address anxiety with listening, explanation, call-bell reassurance.
  • Music therapy, aromatherapy (lavender) — low-level evidence but low risk.

Sleep Assessment Tools

Richards-Campbell Sleep Questionnaire (RCSQ): 5-item visual analogue scale assessing depth, latency, awakenings, return to sleep, and overall quality. Validated for ICU patients; completed by patient each morning.

Pharmacological (If Required)

  • Melatonin 1–5 mg nocte preferred over benzodiazepines/z-drugs in hospitalised patients.
  • Avoid benzodiazepines/anticholinergic sedatives as first choice (delirium risk).
  • Low-dose quetiapine or olanzapine for delirium-associated sleep disruption (specialist-supervised).

Post-ICU Sleep Disruption & PICS

Post-Intensive Care Syndrome (PICS)

Physical, cognitive, and psychological morbidity persisting after ICU discharge. Sleep disorders are a prominent component: up to 60% of ICU survivors report insomnia and sleep quality impairment for months–years after discharge.

Sleep fragmentation during ICU admission (due to noise, light, sedation protocols, mechanical ventilation) disrupts circadian rhythm and normal sleep architecture, with long-lasting effects.

Nursing Role in PICS Prevention

  • ABCDEF Bundle: Awakening and Breathing Coordination, Choice of sedation, Delirium assessment, Early mobilisation, Family engagement.
  • Minimise sedation depth; use light/moderate sedation goals (RASS 0 to -2).
  • Maintain day-night orientation (circadian-aware care delivery).
  • ICU diaries: patients can reconstruct their ICU experience, reducing PTSD and nightmare disorder post-discharge.
  • Follow-up clinic referral: screen for sleep disorders, anxiety, PTSD at 3 months post-discharge.

Shift Work — Nursing Health & Safety

Nurse Sleep Deprivation & Patient Safety

  • Nurses working >12.5-hour shifts or extended overtime have significantly higher medication error rates.
  • Sleep deprivation impairs vigilance, clinical judgment, reaction time, and emotional regulation.
  • Delayed response to deteriorating patients linked to fatigue-impaired situational awareness.
  • WHO and ILO recognise night shift as a Group 2A probable carcinogen (prolonged exposure).

Rotating vs Fixed Night Shifts

Rapid rotation (changing shift direction quickly) is most disruptive. Slow forward rotation (morning → evening → night) is physiologically preferable. Fixed night shifts allow partial circadian adaptation.

Sleep Strategies for Night Shift Nurses

  • Daytime sleep hygiene: Blackout curtains, white noise machine/earplugs, phone on silent, "do not disturb" sign. Communicate schedule to household members.
  • Anchor sleep: Maintain a consistent core sleep window even on days off (prevents extreme circadian disruption).
  • Melatonin: 0.5–3 mg taken 30 minutes before daytime sleep after night shift. Aids initiation but does not fully resynchronise circadian rhythm.
  • Strategic napping: Brief nap (20 min) before night shift; avoid napping >30 min to prevent sleep inertia.
  • Caffeine management: Effective first half of shift; avoid in the last 4–6 hours to prevent sleep disruption post-shift.
  • Light management: Seek bright light at shift start; wear blue-light blocking glasses on commute home.
Fatigue Risk Management: GCC hospitals should implement fatigue management policies including maximum consecutive shifts, mandatory rest periods, and confidential self-reporting of fatigue — aligned with accreditation standards (JCI, CBAHI).

GCC Sleep Medicine Context

Epidemiology in the Gulf

  • OSA prevalence estimated 8–25% of GCC adults (varies by country/BMI). Saudi Arabia studies report up to 34% of obese adults meeting OSA criteria.
  • High-risk demographics: middle-aged males, obese, truck and taxi drivers (driving safety implications).
  • Obesity rates: UAE, Saudi Arabia, Kuwait among world's highest BMI averages — driving OSA burden.
  • Historically limited sleep medicine capacity, but growth: dedicated sleep labs in major centres (King Faisal Specialist Hospital, Cleveland Clinic Abu Dhabi, Hamad Medical Corporation).

Cultural Considerations

  • Qailulah (afternoon nap): Sunnah practice (post-Dhuhr nap). Research supports 20–30 min nap for restored alertness — clinically endorse as beneficial.
  • Ramadan: Sleep phase delay, reduced total sleep time, daytime fasting fatigue. Advise patients with OSA not to miss CPAP use during Suhoor/Iftar sleep periods.
  • Modesty considerations: Female patients may prefer female sleep technician/nurse for PSG setup — address in sleep lab protocols.

Regulatory & Exam Context

  • DHA (Dubai Health Authority) Licensing: Nursing exam assesses sleep disorder knowledge in adult health and critical care modules.
  • DOH (Department of Health, Abu Dhabi): Health Authority licensing exam covers OSA perioperative management and CPAP nursing education.
  • SCFHS (Saudi Commission for Health Specialties): Saudi nursing licensing and specialist exams include sleep disorders as part of respiratory and adult health competencies.
  • Key exam topics: STOP-BANG scoring, CPAP nursing management, CBT-I components, perioperative OSA risk, narcolepsy vs idiopathic hypersomnia, RLS treatment, parasomnias safety.

Key Nursing Responsibilities

  • Screening: STOP-BANG in pre-admissions/pre-operative clinic, ESS in outpatient settings.
  • Education: CPAP initiation, adherence coaching, sleep hygiene, weight management counselling.
  • Safe practice: perioperative OSA airway vigilance, fall prevention with sedating medications.
  • Hospital sleep: implement evidence-based sleep promotion bundles.

Interactive STOP-BANG OSA Risk Screener

Answer 8 yes/no questions to calculate OSA risk score. For clinical decision support — not a diagnostic tool.

S
T
O
P
B
A
N
G

    Question 1
    A patient's polysomnography shows an Apnoea-Hypopnoea Index of 22 events/hour. How is this classified?
    Correct: B — Moderate OSA. AHI 15–29 = moderate. Mild = 5–14. Severe = ≥30/hour.
    Question 2
    Which is the FIRST-LINE treatment for chronic insomnia disorder?
    Correct: C — CBT-I. CBT-I is recommended as first-line treatment for chronic insomnia by all major guidelines (AASM, NICE, EAN). It has superior long-term outcomes compared to pharmacotherapy.
    Question 3
    A STOP-BANG score of 5 indicates which OSA risk level?
    Correct: C — High risk. STOP-BANG: 0–2 = Low risk; 3–4 = Intermediate risk; 5–8 = High risk for moderate-severe OSA.
    Question 4
    REM Sleep Behaviour Disorder (RBD) is strongly associated with which condition as a prodromal feature?
    Correct: C — Parkinson's / DLB. Up to 90% of idiopathic RBD patients develop an alpha-synucleinopathy (PD, DLB, or MSA) over 10–15 years. RBD is the strongest known prodromal marker.
    Question 5
    What ferritin threshold warrants iron supplementation in a patient with Restless Legs Syndrome?
    Correct: C — Less than 75 µg/L. AASM guidelines recommend iron supplementation (oral or IV) in RLS patients with serum ferritin <75 µg/L to replenish central iron stores.
    Question 6
    What defines adequate CPAP adherence according to standard criteria?
    Correct: B — ≥4 hours/night on ≥70% of nights. This is the CMS/AASM standard definition used for CPAP funding/reimbursement and clinical adherence assessment over a 30-day period.
    Question 7
    A nurse is caring for a post-operative patient with known OSA on the surgical ward. The patient received IV morphine PCA. Which assessment priority is MOST important?
    Correct: B — Continuous SpO2 monitoring. OSA patients have increased opioid-induced respiratory depression risk, particularly during REM rebound in the first 24h post-op. Continuous SpO2 monitoring and airway observation is the priority safety intervention.
    Question 8
    Which neurotransmitter/peptide deficiency is pathognomonic of Narcolepsy Type 1?
    Correct: D — Orexin (Hypocretin). Type 1 narcolepsy is caused by autoimmune destruction of hypothalamic orexin-producing neurons. CSF hypocretin-1 <110 pg/mL confirms the diagnosis when cataplexy is present.
    Question 9
    Which component of CBT-I restricts time in bed to match actual sleep time, building homeostatic sleep drive?
    Correct: C — Sleep restriction therapy. This technique limits time in bed to the patient's actual sleep time (minimum 5.5h), building homeostatic pressure. Time in bed is extended by 15 minutes per week when sleep efficiency exceeds 85%.
    Question 10
    A hospitalised patient reports very poor sleep. Which nursing intervention has the STRONGEST evidence for improving sleep in hospital?
    Correct: B — Non-pharmacological sleep bundle. Earplugs/eye masks combined with clustering care to reduce night-time interruptions is the strongest evidence-based nursing intervention. This approach also reduces delirium incidence in ICU patients.